|
Laxman Pai, Opalesque Asia: Biotech and pharma venture capitalist (VC) deal activity will likely exceed $20 billion for the second consecutive year in 2021, said research firm PitchBook.
"These two main areas for VC have grown during the COVID-19 pandemic and investors have ample dry powder to direct money at biotech and pharma firms in 2021," stated the data provider for the private and public equity markets.
Ever-growing capital commitments from LPs looking to break into the biopharma space, coupled with the recycling of profits and liquidity from 2020's IPO market will fuel dealmaking in 2021 to near-record levels, it said.
It also predicted that non-traditional will lead a record 1,600 early- and late-stage VC deals as venture become more ingrained in their investment strategy.
Investing in VC has become much more ingrained within nontraditional investor strategies and as these firms grow even more accustomed to and comfortable with these deals, their penchant for leading venture rounds will continue to grow, it said.
Number of SPAC IPOs will decline YoY in 2021
The number of SPAC IPOs will decline YoY in 2021, and fewer than 30% of 2020 SPACs will close an acquisition.
The deluge of SPAC IPOs in 2020 saw a near quadrupling of IPO count in the space, but for most investors, the establishment of a SPAC program in the current environment was likely driven more by opportunism in a bull market than measured inception of an evergre...................... To view our full article Click here
|
RSS
